Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 2
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) w…
Carcinoma, HepatocellularLiver Cell Carcinoma
Estimated
~$10 – $6,250
Rutgers, The State University of New JerseyNCT05366829
Phase 1
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) mali…
Solid Tumor (Excluding CNS)Liver Cell CarcinomaMalignant Rhabdoid Tumor+7 more
Estimated
~$10 – $6,250
Seattle Children's HospitalNCT07148050
Phase 1
INTERCEPT-GPC3: Interleukin-15 and -21 Armored Glypican-3 Specific Chimeric Antigen Receptor Expressing Autologous T-cells in Adults With GPC3-positive Solid Tumors
This Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors e…
Solid Tumor (Excluding CNS)Hepatocellular CarcinomaLiver Cell Carcinoma+3 more
Estimated
~$10 – $6,250
Seattle Children's HospitalNCT07224568